Mesoblast, Ltd.
Clinical trials sponsored by Mesoblast, Ltd., explained in plain language.
Regenerative medicine company developing cell-based therapies for inflammatory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Shot stem cell treatment aims to quiet aching backs Results expected Jul 2027 (estimated) 🚀 Make-or-break